<DOC>
	<DOC>NCT01073566</DOC>
	<brief_summary>The purpose of this study is to evaluate that Finesse, for prandial insulin bolusing when used in conjunction with basal insulin, achieves equivalent glycemic control when compared to multiple daily injections and to evaluate its preference.</brief_summary>
	<brief_title>Feasibility Study of Finesse for Bolus Prandial Insulin Dosing Compared to Multiple Daily Injections</brief_title>
	<detailed_description>The aim of this feasibility study is to compare efficacy, device satisfaction and quality of life (QOL) in people with type 1 or 2 diabetes delivering mealtime insulin using a novel insulin bolus-patch (Finesseâ„¢; Calibra Medical, Inc., Redwood City, CA) versus current devices that deliver bolus insulin (pen/syringe). All subjects injected their basal insulin using their current pen/syringe.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diabetes mellitus on intensive insulin therapy Insulin pump therapy Current use of NPH or regular insulin Severe hypoglycemic episodes in prior 6 months Unstable cardiac disease, hepatic, or renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Insulin</keyword>
	<keyword>Metabolic Diseases</keyword>
</DOC>